Foghorn Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
December 04, 2020 08:00 ET
|
Foghorn Therapeutics, Inc.
– Well positioned to advance broad pipeline with recent completion of IPO and Merck collaboration – On track to submit an IND for FHD-286 by year end 2020 and for FHD-609 during the first half of...